Best Biotech2050 Podcast Podcasts (2025)

1
Curran Simpson, President & CEO of REGENXBIO, on Gene Therapy, Strategy & Patient-Centered Impact 28:19

Play Pause

7d ago28:19

28:19

Synopsis: When an introverted engineer becomes the President & CEO of REGENXBIO, transformation follows. Curran Simpson joins host Rahul Chaturvedi to unpack his unlikely journey from biotech operations to the C-suite—and how that hands-on experience is reshaping gene therapy's future.They dive into the evolution of REGENXBIO’s pipeline, tackling u…

1
Sergey Jakimov, Founding Partner at LongeVC, on Pragmatic Longevity Investing & Biotech Innovation 31:50

13d ago31:50

31:50

Synopsis: Longevity isn’t just about living longer—it’s about living better. In this insightful episode of Biotech 2050, host Alok Tayi sits down with Sergey Jakimov, Founding Partner at LongeVC, to unpack what it really takes to invest in the future of healthspan.Blending his experience as a medtech entrepreneur, rare disease patient, and venture …

1
Dr. Howard Fillit & Mark Roithmayr of ADDF on Alzheimer’s Innovation, Funding & Biomarkers 41:51

28d ago41:51

41:51

Synopsis:What happens when a world-class scientist and a philanthropic legacy collide with one of medicine’s greatest challenges? Dr. Howard Fillit and Mark Roithmayr of the Alzheimer’s Drug Discovery Foundation (ADDF) join host Alok Tayi for an inspiring conversation on bold science, visionary funding models, and the future of Alzheimer’s research…

1
Stacy Lindborg, Imunon President & CEO, on Bold Biotech, IL-12 Immunotherapy & Phase 3 Trials 17:54

2M ago17:54

17:54

Synopsis: What does bold biotech leadership look like in 2025?In this episode of Biotech 2050, host Alok Tayi sits down with Stacy Lindborg, President & CEO of Imunon, to discuss bold innovation in ovarian cancer treatment and how harnessing the immune system through targeted gene therapy is reshaping survival outcomes.Stacy shares insights from he…

1
Stephanie Sirota, CBO & Partner at RTW Investments, on Biotech Investing, Policy & Bold Bet Building 24:48

2M ago24:48

24:48

Synopsis: What happens when a former journalist becomes one of biotech’s boldest investors? Meet Stephanie Sirota, Chief Business Officer and Partner at RTW Investments, who helped grow the firm from $27 million in assets to a global biotech force. In this engaging conversation with host Rahul Chaturvedi, Stephanie shares her unconventional path in…

1
Steve Tregay on Leading Mission BioCapital as Managing Partner & Fueling Early-Stage Biotech 41:54

3M ago41:54

41:54

Synopsis: Building in biotech isn’t for the faint of heart—especially during a market downturn. But that’s exactly when Steve Tregay, Managing Partner at Mission BioCapital, thrives. A seasoned entrepreneur and founder of Forma Therapeutics, Steven has navigated biotech’s toughest cycles—and emerged stronger each time.Hosted by Rahul Chaturvedi, th…

1
Neil F. McFarlane, President & CEO of Zevra Therapeutics, on Leading Rare Disease Innovation 35:35

4M ago35:35

35:35

Synopsis: In this episode of Biotech2050, host Rahul Chaturvedi sits down with Neil F. McFarlane, President and CEO of Zevra Therapeutics, to explore his unique leadership journey from military nurse to biotech executive. Neil shares reflections from his time at Genzyme and UCB, insights on running a rare disease-focused biotech, and the art of mis…

1
Raj Devraj, President & CEO - Rectify Pharma, on Drug Discovery, Biotech Breakthroughs & Growth 34:03

4M ago34:03

34:03

Synopsis: How do you build a biotech company that disrupts drug discovery and delivers real impact? In this episode of Biotech 2050, host Rahul Chaturvedi speaks with Raj Devraj, President & CEO of Rectify Pharmaceuticals and Venture Partner at Atlas Venture.Raj shares his journey from big pharma to biotech entrepreneurship, the science behind Rect…

1
Revolutionizing CAR T with CRISPR: Rachel Haurwitz, President & CEO of Caribou Biosciences 26:25

4M ago26:25

26:25

Synopsis: Host Rahul Chaturvedi welcomes back Rachel Haurwitz, President & CEO of Caribou Biosciences, for a deep dive into the future of CRISPR-based genome editing and its transformative impact on cell therapy. As a pioneer in the field, Rachel shares the evolution of off-the-shelf CAR T therapies and how Caribou Biosciences is tackling some of t…

1
Liam Killingstad on How Family Offices Quietly Fuel Biotech’s Boldest Innovations 59:19

4M ago59:19

59:19

Synopsis: In this thought-provoking episode of Biotech 2050, host Alok Tayi sits down with Liam Killingstad, Member at Finiam Investments, to unpack the growing influence of family offices in biotech. Driven by his own family's experience with rare cancers, Liam shares how that journey sparked Finiam's deep dive into biotech investing and the co-cr…

1
Clare Terlouw, Head of LifeArc Ventures, on Bridging Biotech’s Funding Gap & Investing for Impact 42:53

5M ago42:53

42:53

Synopsis: Host Alok Tayi sits down with Clare Terlouw, Head of Ventures at LifeArc Ventures, to explore biotech investing from an LP perspective. Clare shares her unique journey—from physiotherapy to investment banking and, ultimately, leading venture investments at a medical charity. The conversation delves into LifeArc’s role in bridging the fund…

1
AI, Biotech, & Venture Capital: Alex Bangash, Founder of Transpose, on Future of Startup Investing 23:49

5M ago23:49

23:49

Synopsis: Venture capital is evolving, and so is biotech. In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of VibeBio, sits down with Alex Bangash, Founder of Transpose, an investment firm backing both startups and funds.With over 20 years of experience in venture investing, Alex shares his unconventional journey from engineering…

1
Empowering Neurodivergent Innovators: Chad Belinsky on Impact, Mentorship, and Atypical Path 35:35

5M ago35:35

35:35

Synopsis: In this special episode of Biotech 2050, Host Alok Tayi, CEO and Co-Founder of VibeBio, delves into the world of neurodivergent entrepreneurship and impact investing with guest Chad Belinsky, founder of AtypicalPath.org. Chad shares his inspiring journey from running a transformative B2B materials company to establishing Atypical Path—a n…

1
Biotech Venture Investing with Narayan Chowdhury, Co-Founder of Franklin Park LLC 27:32

5M ago27:32

27:32

Synopsis: In this episode of Biotech 2050, host Alok Tayi explores the world of biotech venture capital with Narayan Chowdhury, Co-Founder of Franklin Park. As a key player in funding the next wave of biotech breakthroughs, Narayan shares how limited partners (LPs) navigate risk, identify high-potential biotech funds, and decide where to allocate b…

1
David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future 58:17

6M ago58:17

58:17

Synopsis: Join host Alok Tayi as he welcomes David Meeker, CEO of Rhythm Pharmaceuticals, for an inspiring conversation on the transformative journey of rare disease biotech. David shares his incredible path from practicing physician to biotech visionary, recounting his experiences at Genzyme, where he helped shape the rare disease business model a…

1
Pioneering Advances in Cell Therapy: Kristin Yarema, President & CEO of Poseida Therapeutics 38:57

8M ago38:57

38:57

Synopsis: Host Rahul Chaturvedi leads an insightful conversation with Dr. Kristin Yarema, President and CEO of Poseida Therapeutics. Kristin shares the inspiring journey of her career, from her roots in science to leadership roles in big pharma, culminating in her move to biotech entrepreneurship. She reflects on pivotal experiences at Novartis and…

1
Bharatt Chowrira, CEO & Eric Elenko, CoFounder & President of PureTech on Biotech Growth 44:44

8M ago44:44

44:44

Synopsis: In this insightful conversation on Biotech2050, host Rahul Chaturvedi sits down with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder and President of PureTech Health. They explore the company’s pioneering R&D model and how it reshapes drug development by focusing on solving specific problems rather than pushing predefined solutions. Bh…

1
Rob Williamson, CEO of Triumvira, on Biotech’s High-Stakes Path and Cell Therapy Innovations 23:45

8M ago23:45

23:45

Synopsis: Rob Williamson, CEO of Triumvira, joins Biotech 2050 host, Rahul Chaturvedi, to discuss his dynamic career from economics to biotech, tackling the volatile capital markets, and navigating high-stakes decisions in cell therapy. He shares insights on therapeutic developments in cell therapy, the pressures of solid tumor research, and the ev…

1
Gene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson's Breakthroughs 32:01

9M ago32:01

32:01

Biotech2050 Host, Rahul Chaturvedi, engages with Gene Mack, Interim CEO and CFO of Gain Therapeutics, as he shares his journey from aspiring neurosurgeon to biotech leader. Gene reflects on his career shift from clinical research to Wall Street and eventually operational roles in biotech. He details the development of Gain's lead asset, GT02287, wh…

1
Revolutionizing Heart Health: Bitterroot Bio’s Bold Vision with CEO Pavan Cheruvu 43:07

9M ago43:07

43:07

Synopsis: Discover how Bitterroot Bio is poised to revolutionize cardiovascular health in this captivating conversation between host Rahul Chaturvedi and CEO Pavan Cheruvu. Pavan opens up about his inspiring journey from engineering to leading a biotech company at the forefront of cardio-immunology. Learn how his visionary leadership is driving inn…

1
Inside the Journey of Abcuro: CEO Alex Martin on Leadership, IBM, and the Future of Biotech 36:58

9M ago36:58

36:58

Synopsis: In this episode of Biotech 2050, Alex Martin, CEO of Abcuro, sits down with host Rahul Chaturvedi to share his inspiring journey from aspiring actor to biotech trailblazer. Alex reveals how his unique background shaped his leadership approach as he drives Abcuro’s groundbreaking work on Inclusion Body Myositis (IBM), a rare muscle disease…

1
Precision Neuroscience Breakthroughs: Abe Ceesay, CEO of Rapport Therapeutics I Future of Biotech 47:12

9M ago47:12

47:12

Synopsis: Abe Ceesay, CEO of Rapport Therapeutics, sits down with host Rahul Chaturvedi to reveal how precision neuroscience is driving revolutionary treatments for neurological disorders. They explore Rapport’s cutting-edge lead program targeting focal epilepsy and discuss the groundbreaking advancements that are reshaping the landscape of drug de…

1
Dr. Dave Bearss, Co-Founder & CEO of Halia, on Pioneering Genetic Discoveries to Defeat Alzheimer’s 35:36

9M ago35:36

35:36

Synopsis: Explore the forefront of biotech innovation as host Rahul Chaturvedi interviews Dr. Dave Bearss, Co-Founder & CEO of Halia Therapeutics, in this engaging episode of Biotech 2050. Dr. Bearss shares the story behind Halia’s pioneering genetic discoveries and their mission to tackle Alzheimer’s disease. Learn about the science driving breakt…

1
Breaking Biotech Barriers: Avidity President & CEO Sarah Boyce on RNA’s Next Frontier 35:08

10M ago35:08

35:08

Synopsis: In this episode, host Rahul Chaturvedi interviews Sarah Boyce, President & CEO of Avidity Biosciences, as she shares her dynamic journey from big pharma to leading groundbreaking advancements in RNA therapeutics. Sarah delves into overcoming drug delivery challenges, the transformative potential of genetic medicine, and Avidity’s mission …

1
Advancing Drug Discovery with Cutting-Edge AI & Team Synergy: Fabrice Chouraqui, CEO of Cellarity 31:40

11M ago31:40

31:40

Synopsis:Step into the future of biotech as host Rahul Chaturvedi delves into an exclusive conversation with Fabrice Chouraqui, CEO of Cellarity, as he unveils the groundbreaking ways AI is revolutionizing drug discovery. Fabrice will take you behind the scenes of Cellarity’s trailblazing approach, revealing how their pioneering technology is accel…

1
Redefining Dementia Care: CervoMed's Bold Journey with CEO John Alam 24:38

11M ago24:38

24:38

Synopsis:Get ready for an insightful conversation as host Rahul Chaturvedi connects with John Alam, CEO of CervoMed, to uncover the revolutionary advancements transforming dementia treatment, with a spotlight on Dementia with Lewy Bodies (DLB). John shares his remarkable journey from practicing medicine to leading cutting-edge biotech innovations, …

1
From Banking to Biotech: Renée Aguiar-Lucander, CEO of Calliditas, on Rare Disease Innovation 30:51

11M ago30:51

30:51

Synopsis:Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, appears on this insightful episode of Biotech 2050 with host Rahul Chaturvedi. Renée shares her unconventional journey from investment banking to biotech leadership, underscoring the crucial role of capital markets and regulatory strategies. The discussion explores the unique challenge…

1
Autoimmune Innovations: Insights from Marshall Fordyce, Founder & CEO, Vera Therapeutics on Biotech 32:50

12M ago32:50

32:50

Synopsis: In this engaging episode, host, Rahul Chaturvedi welcomes Marshall Fordyce, Founder and CEO of Vera Therapeutics, to discuss his transformative journey from physician to biotech entrepreneur. Marshall shares the story behind Vera Therapeutics' strategic pivot to focus on IG nephropathy and their development of atacicept, a promising B-cel…

1
Transforming Gene Therapy: Exclusive Insights from Zandy Forbes, President & CEO of MeiraGTx 50:25

12M ago50:25

50:25

Synopsis:Zandy Forbes, Founder, President, and CEO of MeiraGTx, joins host Rahul Chaturvedi in this compelling episode. Zandy shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company. S…

1
Biotech Breakthroughs: Jeb Keiper, CEO of Nimbus Therapeutics, Discusses Their Innovative Journey 35:03

12M ago35:03

35:03

Synopsis:Dive into this episode of Biotech 2050 where host Rahul Chaturvedi interviews Jeb Keiper, CEO of Nimbus Therapeutics. Discover Jeb's fascinating journey from MIT chemist to industry leader, and the unique strategies that have driven Nimbus's success. Jeb discusses the evolution of biotech financing, the importance of taking bold risks, and…

1
Revolutionizing Proteomics: Sujal Patel, Co-Founder & CEO of Nautilus, on Drug Development 36:55

1y ago36:55

36:55

Synopsis:Sujal Patel, co-founder and CEO of Nautilus Biotechnology, discusses their innovative work in proteomics and its impact on drug development. Sujal shares his transition from tech to biotech, the formation of Nautilus with Parag Mallick, and their revolutionary approach using multi-affinity probes. The conversation highlights the importance…

1
Exploring Neuroscience, Psychiatry, & Rare Diseases, Bruce Leuchter, President & CEO, Neurvati 51:22

1y ago51:22

51:22

Synopsis: In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of Vibe Bio, speaks with Dr. Bruce Leuchter, President and CEO of Neurvati Neuroscience. They discuss capital markets, neurology, psychiatry, and Neurvati's work in ultra-rare diseases. Dr. Leuchter shares his journey from clinical training to leadership at Neurvati. The …

1
Transformative Oncology Innovations, Ken Keller, President & CEO, Daiichi Sankyo, Inc. 28:18

1y ago28:18

28:18

Synopsis: In this episode of BioTech 2050, Ken Keller, President and CEO of Daiichi Sankyo, Inc. provides an in-depth look into the company's transformation from a cardiovascular-focused organization to a leader in oncology. He discusses the groundbreaking advancements in antibody-drug conjugates (ADCs), particularly highlighting the success of the…

1
Strategic Leadership and Autoimmune Breakthroughs, Praveen Tipimeni, CEO 34:03

1y ago34:03

34:03

Synopsis: In this episode of Biotech2050, Praveen Tipirneni, CEO of Morphic Therapeutics, shares insights on Morphic’s strategic IPO, the rising interest in autoimmune treatments, the journey of their alpha 4 beta 7 program, and maintaining a conservative yet opportunistic approach in biotech. He also discusses the importance of building a strong t…

1
Innovative Approaches to Cancer Therapies, Robert Ang, President and CEO 30:09

1y ago30:09

30:09

Synopsis: In this episode of BioTech 2050, Robert Ang, CEO of Vor Bio, shares insights on the current state of cancer therapies and next-gen modalities. He discusses Vor Bio's work on shielded stem cell transplants and CAR T-cell therapies targeting hematologic malignancies like AML and MDS. Robert also talks about his experience serving on boards …

1
Tech-Biotech Convergence, Growth, and Global Lessons, Vik Bajaj, Co-founder and CEO 31:05

1y ago31:05

31:05

Synopsis: In this episode of Biotech2050, Vik Bajaj, Co-founder and CEO of Foresite Labs, delves into the convergence of tech and biotech, hyper-growth phases in biotech companies, changes in finance and capital markets, and lessons from global healthcare systems, particularly the UK. He highlights the transformative potential of technology in biot…

1
Advancing and Revolutionizing Sickle Cell Treatment, Ted Love, Chair and BOD 27:00

1y ago27:00

27:00

Synopsis: In this episode of Biotech2050, Dr. Ted Love, former CEO of Global Blood Therapeutics and Current Chairman of BIO, shares insights on sickle cell breakthroughs, transitioning from academia to research, navigating a tight funding environment, and protecting an innovative ecosystem to benefit patients.Biography:Dr. Ted Love is the chair of …

1
Demystifying Drug Discovery, Ray Stevens, CEO, Structure Therapeutics 31:57

1+ y ago31:57

31:57

Synopsis: In this episode of the Biotech 2050 podcast, host Rahul Chaturvedi engages in a thought-provoking conversation with Ray Stevens, a prominent figure in the biotech industry who co-founded Structure Therapeutics. Ray's extensive experience and pivotal role in advancing structure-based drug discovery make him a compelling guest for biotech e…

1
Navigating The Evolving Landscape of Inflammation Research, Scott Megaffin, CEO, Adiso Therapeutics 27:55

1+ y ago27:55

27:55

Synopsis: In this episode of Biotech2050, Scott Megaffin, CEO of Adiso Therapeutics, shares valuable insights on the challenges and opportunities in the biotech industry. His deep involvement in the pharmaceutical and biopharmaceutical sector has shaped his strategic approach to leadership and business management. Scott emphasizes the importance of…

1
Biotech's Game Changers & Revolutionizing Therapeutics, Dr. Mammen, CEO, FogPharma 50:36

1+ y ago50:36

50:36

Synopsis: In this episode of the Biotech2050 podcast, Dr. Mathai Mammen, CEO of FogPharma, shares valuable insights into the future trends of the biotech industry and the development of peptide-based therapeutics. Dr. Mammen's extensive career trajectory, from academia to leading pharmaceutical organizations, provides a comprehensive understanding …

1
The Race to Cure Untreatable Cancers, Ken Galbraith, Chair and CEO, Zymeworks 40:37

1+ y ago40:37

40:37

Synopsis: In the recent episode of Biotech2050, Ken Galbraith, CEO of Zymeworks, shares profound insights into the biotech industry, leadership, and the complexities of developing innovative treatments for challenging cancers. Galbraith's accidental entry into biotech in 1987, despite lacking prior experience, led to his pivotal role in establishin…

1
Innovation in Precision Therapies for CNS Diseases, Craig Chambliss, Co-Founder and CEO, Neurelis 36:41

1+ y ago36:41

36:41

Synopsis: In this episode of Biotech2050, host Alok Tayi engages in a profound conversation with Craig Chambliss, CEO and co-founder of Neurellis, delving into their strategic advancements in precision therapies for CNS diseases. Chambliss shares his journey, highlighting his finance and accounting background and pivotal roles in pharmaceutical com…

1
Unlocking Genetic Medicine's Full Potential, Tuyen Ong, CEO, Ring Therapeutics 23:07

1+ y ago23:07

23:07

Synopsis: On the Biotech2050 podcast, Tuyen Ong, CEO at Ring Therapeutics and CEO partner at flagship pioneering, shared his journey from a medical background to leading innovative gene therapy companies, highlighting the importance of cross-disciplinary expertise in driving biotech advancements. His insights into the gene therapy landscape and the…

1
Aging Biology and The Power of Human Data, Kristen Fortney, Co-Founder and CEO, BioAge 26:45

1+ y ago26:45

26:45

Synopsis: In a recent episode of Biotech2050, hosted by Alok Tayi, Kristen Fortney, CEO of BioAge, provides valuable insights into the evolving landscape of aging biology and the innovative approach BioAge is taking to identify therapeutic targets. Kristen's background in aging biology, genetics, and statistics underscores her expertise in the fiel…

1
The Intersection Of Tech and Biotech, Chris Gibson, Co-Founder & CEO, Recursion 39:42

1+ y ago39:42

39:42

Synopsis: In this episode of the Biotech2050 podcast, Chris Gibson, the co-founder and CEO of Recursion, shares insights on the intersection of technology and biotech, emphasizing the importance of adaptability and diverse partnerships in driving innovation. Gibson's journey from pursuing an MD-PhD program with a focus on merging engineering and me…

1
Psychedelics, Longevity, and Wellbeing, Christian Angermayer, Founder, Apeiron Investment Group 46:09

1+ y ago46:09

46:09

Synopsis: Christian Angermayer, a prominent investor and entrepreneur in the biotech industry, shares valuable insights in the Biotech2050 podcast, shedding light on the challenges and opportunities within the sector. Drawing from his extensive experience, Angermayer emphasizes the importance of making biotech more accessible to a broader audience …

1
Navigating Platform vs Product Tension, David Kirn, Co-Founder & CEO, 4DMT 33:34

1+ y ago33:34

33:34

Synopsis: In this episode of the Biotech2050 podcast, David Kirn, CEO of 4D Molecular Therapeutics, shares invaluable insights for aspiring entrepreneurs in the biotech industry. Kirn discusses the development of his company's platform that integrates gene therapy and directed evolution to create innovative treatments for genetic diseases. By utili…

1
Adapting Through Disruption in Biotech, David Esposito, President & CEO, ONL Therapeutics 25:30

1+ y ago25:30

25:30

Synopsis:In this episode of the Biotech2050 podcast, David Esposito, CEO of ONL Therapeutics, provides valuable insights into the challenges and opportunities in the field of ophthalmology. Esposito's extensive career journey, from the United States Military Academy to leading ONL Therapeutics, underscores his deep understanding of the industry. He…

1
Overcoming Capital Challenges in Biotech, Jak Knowles, President & CEO, Affini-T Therapeutics 26:10

1+ y ago26:10

26:10

Synopsis: In this episode of the Biotech2050 podcast, Jak Knowles, co-founder of Affini-T Therapeutics, shares valuable insights into the challenges faced by bootstrapped biotech companies and the significance of venture capital in the industry. Knowles discusses the importance of finding key partners and securing intellectual property early on, sh…

1
A novel approach to advancing breast cancer therapy, Sean Bohen, President & CEO, Olema Oncology 20:12

1+ y ago20:12

20:12

Synopsis: Sean Bohen, M.D., Ph.D., is the President and CEO of Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women’s cancers. We’re excited to welcome Sean back to the podcast – he last appeared on episode 130 in late 2022. Sean provides an update on all the exciting things that have happened at Olema sinc…